BioPharma Resources

Investigational drug · Phase 3

4D-150

Also called: 3E10 vg, eye, 3x10^10 vg

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

5 still active

All registered trials

5

Any phase or sponsor naming "4D-150"

First trial start

2021

Dec 9, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "4D-150", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Neovascular Age-Related Macular Degeneration (nAMD)
  • Diabetic Macular Edema (DME)
  • Neovascular (Wet) Age-Related Macular Degeneration
  • Diabetic Macular Edema
  • Diabetic Retinopathy
  • Macular Neovascularization Secondary to Age-Related Macular Degeneration

Approved drugs for the same conditions: Wet macular degeneration · Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "4D-150" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 357,991 on PubMed

Also in development for Neovascular Age-Related Macular Degeneration (nAMD)

  • OTX-TKIaxitinib implantPhase 33 trials

    Ocular Therapeutix, Inc. · Neovascular Age-related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD)

  • QL1207HPhase 31 trial

    Qilu Pharmaceutical Co., Ltd. · Neovascular Age-Related Macular Degeneration (nAMD)

  • KHK4951Phase 22 trials

    Kyowa Kirin Co., Ltd. · Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.